Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J B Cannon

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Science (New York, N.Y.)|June 9, 1995
Oak Ridge's StrengthsJ B Cannon
Journal of Pharmaceutical Sciences|May 1, 1993
Pharmaceutics and drug delivery aspects of heme and porphyrin therapyJ B Cannon
Biochimica Et Biophysica Acta|July 16, 1980
Determination of the equilibrium constant for the binding of ferricytochrome c to phospholipid vesicles and the effect of binding on the reduction rate of cytochrome cJ B Cannon, J E Erman
Biochemical and Biophysical Research Communications|September 14, 1978
The effect of phospholipid vesicles on the kinetics of reduction of cytochrome cJ B Cannon, J E Erman
Targeted Diagnosis and Therapy|January 1, 1990
Immunoconjugates in drug delivery systemsJ B Cannon, H W Hui
The New England Journal of Medicine|January 15, 1981
Aluminum pots as a source of dietary aluminumJ A Trapp, J B Cannon
PDA Journal of Pharmaceutical Science and Technology|March 1, 1995
The effect of aggregation inhibitors and antioxidants on the stability of hemin solutionsJ B Cannon, M H Yunker, N Luoma
Journal of Pharmaceutical Sciences|August 1, 1995
Physicochemical properties of A-75998, an antagonist of luteinizing hormone releasing hormoneJ B Cannon, S L Krill, W R Porter
Pharmaceutical Research|May 1, 1993
Targeted delivery of a heme oxygenase inhibitor with a lyophilized liposomal tin mesoporphyrin formulationJ B Cannon, C Martin, G S Drummond, et al.
Journal of Drug Targeting|January 1, 1996
Alternate drug delivery routes for A-71623, a potent cholecystokinin-A receptor agonist tetrapeptideJ B Cannon, L A Adjei, M Y Lu, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Science (New York, N.Y.)|June 9, 1995
Oak Ridge's StrengthsJ B Cannon
Journal of Pharmaceutical Sciences|May 1, 1993
Pharmaceutics and drug delivery aspects of heme and porphyrin therapyJ B Cannon
Biochimica Et Biophysica Acta|July 16, 1980
Determination of the equilibrium constant for the binding of ferricytochrome c to phospholipid vesicles and the effect of binding on the reduction rate of cytochrome cJ B Cannon, J E Erman
Biochemical and Biophysical Research Communications|September 14, 1978
The effect of phospholipid vesicles on the kinetics of reduction of cytochrome cJ B Cannon, J E Erman
Targeted Diagnosis and Therapy|January 1, 1990
Immunoconjugates in drug delivery systemsJ B Cannon, H W Hui
The New England Journal of Medicine|January 15, 1981
Aluminum pots as a source of dietary aluminumJ A Trapp, J B Cannon
PDA Journal of Pharmaceutical Science and Technology|March 1, 1995
The effect of aggregation inhibitors and antioxidants on the stability of hemin solutionsJ B Cannon, M H Yunker, N Luoma
Journal of Pharmaceutical Sciences|August 1, 1995
Physicochemical properties of A-75998, an antagonist of luteinizing hormone releasing hormoneJ B Cannon, S L Krill, W R Porter
Pharmaceutical Research|May 1, 1993
Targeted delivery of a heme oxygenase inhibitor with a lyophilized liposomal tin mesoporphyrin formulationJ B Cannon, C Martin, G S Drummond, et al.
Journal of Drug Targeting|January 1, 1996
Alternate drug delivery routes for A-71623, a potent cholecystokinin-A receptor agonist tetrapeptideJ B Cannon, L A Adjei, M Y Lu, et al.
Pageof 2